AbbVie | ABBV

Stock Price
164.21
Daily Change
2.59 1.60%
Monthly
1.11%
Yearly
14.60%
Q2 Forecast
160.71
Peers Price Chg Day Year Date
Eisai 7,006.00 142.00 2.07% -16.45% May/16
AbbVie 164.21 2.59 1.60% 14.60% May/15
Abbott 104.25 0.76 0.73% -4.70% May/15
ALKERMES 24.24 -0.25 -1.02% -21.86% May/15
Amgen 319.14 7.28 2.34% 40.05% May/15
AstraZeneca 12,172.00 -74.00 -0.60% 0.85% May/15
Biogen 235.43 8.30 3.65% -23.46% May/15
BioMarin Pharmaceutical 80.40 0.75 0.94% -12.63% May/15
Bristol-Myers Squibb 44.61 -0.19 -0.42% -33.44% May/15
Gilead Sciences 67.00 -0.66 -0.97% -14.45% May/15
GlaxoSmithKline 1,812.50 2.50 0.14% 23.64% May/15
J&J 152.68 1.24 0.82% -4.18% May/15
Eli Lilly 787.02 22.84 2.99% 80.24% May/15
Medtronic 84.95 0.42 0.50% -4.44% May/15
Merck 131.77 3.08 2.39% 13.52% May/15
Neurocrine Biosciences 142.00 3.52 2.54% 50.54% May/15
Novartis 93.30 -0.19 -0.20% 0.86% May/15
Pacira 30.08 -0.74 -2.40% -27.11% May/15
Pfizer 28.84 0.46 1.62% -22.08% May/15
Perrigo 30.26 -0.09 -0.30% -7.87% May/15
Ultragenyx Pharmaceutical 41.12 0.15 0.37% -11.93% May/15
Regeneron Pharmaceuticals 978.21 -7.20 -0.73% 31.78% May/15
Roche Holding 227.50 2.90 1.29% -19.41% May/15
Sanofi 90.56 -1.13 -1.23% -9.75% May/15
UCB 122.55 2.30 1.91% 43.50% May/15
United Therapeutics 272.69 2.91 1.08% 28.60% May/15
Vertex Pharmaceuticals 437.40 8.63 2.01% 26.73% May/15
Zoetis 173.12 4.33 2.57% -4.59% May/15

Indexes Price Day Year Date
US500 5312 61.47 1.17% 27.72% May/16

AbbVie traded at $164.21 this Wednesday May 15th, increasing $2.59 or 1.60 percent since the previous trading session. Looking back, over the last four weeks, AbbVie gained 1.11 percent. Over the last 12 months, its price rose by 14.60 percent. Looking ahead, we forecast AbbVie to be priced at 160.71 by the end of this quarter and at 154.57 in one year, according to Trading Economics global macro models projections and analysts expectations.

AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.